GGrantIndex
← Leaderboards

Leo E Otterbein

University Of Pittsburgh At Pittsburgh

$8,123,287
Attributed
$13,824,873
Total exposure
11
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.8M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$13,824,873 · 11

By mechanism

R01$10,664,590 · 5
R44$1,497,651 · 1
R41$1,133,192 · 3
R56$304,500 · 1
R43$224,940 · 1

Top collaborators

Most similar at University Of Pittsburgh At Pittsburgh

Same institution · by research overlap

Others in their field

Top investigators on “Carbon Monoxide

Research focus

Carbon MonoxideIn VivoLiteratureDoseHemeAnimal ModelPreventInnovationPre-ClinicalNitric OxideAnimalsGasesBaseKineticsInflammationOralPropertyModalitySafetyDrug KineticsToxic EffectImproved OutcomeReperfusion InjuryFormulation

Grant awards (34)

Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney Injury$705,716
R01 · FY2025 · DK
Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney Injury$678,976
R01 · FY2024 · DK
Examining Carbon Monoxide to Treat Inflammatory Conditions using Experimental Colitis Models$708,873
R01 · FY2023 · DK
Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney Injury$707,586
R01 · FY2023 · DK
Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury$299,894
R41 · FY2023 · AI
Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney Injury$750,347
R01 · FY2022 · DK
Examining Carbon Monoxide to Treat Inflammatory Conditions using Experimental Colitis Models$708,873
R01 · FY2022 · DK
Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury$299,894
R41 · FY2022 · AI
Examining Carbon Monoxide to Treat Inflammatory Conditions using Experimental Colitis Models$708,873
R01 · FY2021 · DK
HBI-002 to Treat Ulcerative Colitis$75,058
R41 · FY2021 · DK
HBI-002 to Prevent Anthracycline-Related Cardiotoxicity$16,896
R41 · FY2021 · HL
Examining Carbon Monoxide to Treat Inflammatory Conditions using Experimental Colitis Models$707,948
R01 · FY2020 · DK
HBI-002 to Prevent Anthracycline-Related Cardiotoxicity$222,338
R41 · FY2020 · HL
HBI-002 to Treat Ulcerative Colitis$219,112
R41 · FY2020 · DK
Examining Carbon Monoxide to Treat Inflammatory Conditions using Experimental Colitis Models$733,350
R01 · FY2019 · DK
HBI-002 to Treat Traumatic Injury$56,476
R43 · FY2019 · GM
HBI-002 to Treat Traumatic Injury$168,464
R43 · FY2018 · GM
HBI-002 to Treat Delayed Graft Function in Kidney Transplant$635,033
R44 · FY2017 · DK
HBI-002 to Treat Delayed Graft Function in Kidney Transplant$862,618
R44 · FY2016 · DK
Endogenous Gas Molecules As Transcription Factors$341,075
R01 · FY2012 · GM · contact PI
Endogenous Gas Molecules As Transcription Factors$341,075
R01 · FY2011 · GM · contact PI
HemeOxygenase-1 and Transplant Tolerance$304,500
R56 · FY2011 · AI · contact PI
Endogenous Gas Molecules As Transcription Factors$344,189
R01 · FY2010 · GM · contact PI
Endogenous Gas Molecules As Transcription Factors$345,600
R01 · FY2009 · GM · contact PI
Carbon Monoxide to Prevent Circulatory Collapse$402,977
R01 · FY2007 · HL · contact PI
Carbon Monoxide to Prevent Circulatory Collapse$415,013
R01 · FY2006 · HL · contact PI
Anti-Inflammatory Effects of Carbon Monoxide in the Lung$332,010
R01 · FY2006 · HL · contact PI
Carbon Monoxide to Prevent Circulatory Collapse$425,000
R01 · FY2005 · HL
Anti-Inflammatory Effects of Carbon Monoxide in the Lung$340,000
R01 · FY2005 · HL
Carbon Monoxide to Prevent Circulatory Collapse$308,129
R01 · FY2004 · HL
Anti-Inflammatory Effects of Carbon Monoxide in the Lung$289,583
R01 · FY2004 · HL
Carbon Monoxide to Prevent Circulatory Collapse$48,846
R01 · FY2004 · HL
Anti-Inflammatory Effects of Carbon Monoxide in the Lung$1
R01 · FY2004 · HL
Anti-Inflammatory Effects of Carbon Monoxide in the Lung$320,550
R01 · FY2003 · HL